國立虎尾科技大學 |

Chronic Myeloid Leukemia

Record Type:	Language materials, printed : Monograph/item
Title/Author:	Chronic Myeloid Leukemia/ edited by Rüdiger Hehlmann.
other author:	Hehlmann, Rüdiger.
Description:	IX, 273 p. 42 illus., 35 illus. in color.online resource. :
Contained By:	Springer Nature eBook
Subject:	Oncology . -
Online resource:	https://doi.org/10.1007/978-3-030-71913-5
ISBN:	9783030719135

Chronic Myeloid Leukemia
Chronic Myeloid Leukemia[electronic resource] /edited by Rüdiger Hehlmann. - 2nd ed. 2021. - IX, 273 p. 42 illus., 35 illus. in color.online resource. - Hematologic Malignancies,2197-9774. - Hematologic Malignancies,.

Cytogenetics of Chronic Myeloid Leukemia (CML) -- The Biology and Pathogenesis of Chronic Myeloid Leukaemia -- Epidemiology of Chronic Myeloid Leukemia.-Imatinib and the first line CML Therapy -- CML Therapy: A Focus on Second and Third Generation Tyrosine Kinase Inhibitors -- Adverse events associated with ATP-competitive BCR-ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia -- Pharmacoeconomic considerations for tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia -- Standardization of molecular monitoring for chronic myeloid leukemia: 2021 update -- Prognostic Scores for Patients with Chronic Myeloid Leukemia under Particular Consideration of Disease-Specific Death -- A Review and an Update of European LeukemiaNet Recommendations for the Management of Chronic Myeloid Leukemia -- The Role of Hematopoietic Stem Cell Transplantation in CML -- CML end-phase and blast crisis: implications and management -- The Interferon-alpha Revival in CML -- Managing Pregnancy in Chronic Myeloid Leukemia -- Response-Related Predictors of Survival and of Treatment Free Remission in CML -- Discontinuation or cessation of tyrosine kinase inhibitor treatment in Chronic myeloid leukemia patients with deep molecular response. .

This book provides state-of-the-art reviews of key issues and recent developments relating to chronic myeloid leukemia (CML), acquainting the reader with advances in research, treatment, and promotion of public health. Among the management topics addressed are the choices, advantages, and pitfalls of first-, second-, and third-line treatments; the European LeukemiaNet recommendations; management of adverse effects of tyrosine kinase inhibitors (TKI); management of CML blast crisis; management of pregnancy in the context of CML; the role of hematopoietic cell transplantation; the current experience with TKI discontinuation; and the value of interferon α in improving the outcome of TKI treatment. Various aspects of relevance to treatment outcome are discussed, including prognostic scores, molecular monitoring (principles and interlaboratory standardization), and response-related predictors of survival. Furthermore, updates are provided on the increasing prevalence of CML and its implications and on the changing cost of care for CML, taking into account the impact of availability of generic imatinib. .

ISBN: 9783030719135

Standard No.: 10.1007/978-3-030-71913-5doiSubjects--Topical Terms:

1253469
Oncology .

LC Class. No.: RC254-282

Dewey Class. No.: 616.994

Chronic Myeloid Leukemia
LDR:03732nam a22004095i 4500 001 1055143
003 DE-He213
005 20210921151712.0
007 cr nn 008mamaa
008 220103s2021 sz | s |||| 0|eng d
020 $a 9783030719135 $9 978-3-030-71913-5
024 7 $a 10.1007/978-3-030-71913-5 $2 doi
035 $a 978-3-030-71913-5
050 4 $a RC254-282
072 7 $a MJCL $2 bicssc
072 7 $a MED062000 $2 bisacsh
072 7 $a MJCL $2 thema
082 0 4 $a 616.994 $2 23
245 1 0 $a Chronic Myeloid Leukemia $h [electronic resource] / $c edited by Rüdiger Hehlmann.
250 $a 2nd ed. 2021.
264 1 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2021.
300 $a IX, 273 p. 42 illus., 35 illus. in color. $b online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
347 $a text file $b PDF $2 rda
490 1 $a Hematologic Malignancies, $x 2197-9774
505 0 $a Cytogenetics of Chronic Myeloid Leukemia (CML) -- The Biology and Pathogenesis of Chronic Myeloid Leukaemia -- Epidemiology of Chronic Myeloid Leukemia.-Imatinib and the first line CML Therapy -- CML Therapy: A Focus on Second and Third Generation Tyrosine Kinase Inhibitors -- Adverse events associated with ATP-competitive BCR-ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia -- Pharmacoeconomic considerations for tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia -- Standardization of molecular monitoring for chronic myeloid leukemia: 2021 update -- Prognostic Scores for Patients with Chronic Myeloid Leukemia under Particular Consideration of Disease-Specific Death -- A Review and an Update of European LeukemiaNet Recommendations for the Management of Chronic Myeloid Leukemia -- The Role of Hematopoietic Stem Cell Transplantation in CML -- CML end-phase and blast crisis: implications and management -- The Interferon-alpha Revival in CML -- Managing Pregnancy in Chronic Myeloid Leukemia -- Response-Related Predictors of Survival and of Treatment Free Remission in CML -- Discontinuation or cessation of tyrosine kinase inhibitor treatment in Chronic myeloid leukemia patients with deep molecular response. .
520 $a This book provides state-of-the-art reviews of key issues and recent developments relating to chronic myeloid leukemia (CML), acquainting the reader with advances in research, treatment, and promotion of public health. Among the management topics addressed are the choices, advantages, and pitfalls of first-, second-, and third-line treatments; the European LeukemiaNet recommendations; management of adverse effects of tyrosine kinase inhibitors (TKI); management of CML blast crisis; management of pregnancy in the context of CML; the role of hematopoietic cell transplantation; the current experience with TKI discontinuation; and the value of interferon α in improving the outcome of TKI treatment. Various aspects of relevance to treatment outcome are discussed, including prognostic scores, molecular monitoring (principles and interlaboratory standardization), and response-related predictors of survival. Furthermore, updates are provided on the increasing prevalence of CML and its implications and on the changing cost of care for CML, taking into account the impact of availability of generic imatinib. .
650 0 $a Oncology . $3 1253469
650 0 $a Hematology. $3 645254
650 1 4 $a Oncology. $3 593951
700 1 $a Hehlmann, Rüdiger. $e editor. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1271017
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
776 0 8 $i Printed edition: $z 9783030719128
776 0 8 $i Printed edition: $z 9783030719142
776 0 8 $i Printed edition: $z 9783030719159
830 0 $a Hematologic Malignancies, $x 2197-9766 $3 1253495
856 4 0 $u https://doi.org/10.1007/978-3-030-71913-5
912 $a ZDB-2-SME
912 $a ZDB-2-SXM
950 $a Medicine (SpringerNature-11650)
950 $a Medicine (R0) (SpringerNature-43714)